California Public Employees Retirement System Lowers Stake in Amedisys, Inc. (NASDAQ:AMED)

California Public Employees Retirement System decreased its position in shares of Amedisys, Inc. (NASDAQ:AMEDGet Rating) by 7.2% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 64,184 shares of the health services provider’s stock after selling 4,958 shares during the quarter. California Public Employees Retirement System’s holdings in Amedisys were worth $6,747,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. grew its stake in Amedisys by 3.7% in the 1st quarter. BlackRock Inc. now owns 3,896,785 shares of the health services provider’s stock worth $671,378,000 after acquiring an additional 138,484 shares during the period. Wellington Management Group LLP grew its stake in Amedisys by 3.5% in the 1st quarter. Wellington Management Group LLP now owns 1,875,274 shares of the health services provider’s stock worth $323,092,000 after acquiring an additional 62,863 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Amedisys by 23.5% during the 1st quarter. JPMorgan Chase & Co. now owns 1,384,041 shares of the health services provider’s stock valued at $238,457,000 after buying an additional 263,275 shares during the period. Mackenzie Financial Corp grew its stake in shares of Amedisys by 67.7% during the 1st quarter. Mackenzie Financial Corp now owns 956,780 shares of the health services provider’s stock valued at $164,844,000 after buying an additional 386,411 shares during the period. Finally, State Street Corp grew its stake in shares of Amedisys by 4.9% during the 1st quarter. State Street Corp now owns 871,346 shares of the health services provider’s stock valued at $150,124,000 after buying an additional 40,486 shares during the period. Institutional investors and hedge funds own 93.36% of the company’s stock.

Wall Street Analyst Weigh In

AMED has been the subject of several research reports. Royal Bank of Canada lowered their price objective on shares of Amedisys from $165.00 to $139.00 and set an “outperform” rating for the company in a research note on Monday, October 31st. Jefferies Financial Group reissued a “buy” rating and set a $150.00 price objective on shares of Amedisys in a research note on Wednesday, November 2nd. Truist Financial lowered their price objective on shares of Amedisys from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Friday, October 28th. StockNews.com raised shares of Amedisys from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on shares of Amedisys from $175.00 to $165.00 and set a “buy” rating for the company in a research report on Monday, October 24th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $136.13.

Amedisys Stock Performance

Shares of Amedisys stock opened at $91.25 on Friday. The firm has a market cap of $2.96 billion, a PE ratio of 24.60, a price-to-earnings-growth ratio of 2.15 and a beta of 0.99. The firm’s 50-day simple moving average is $96.21 and its 200-day simple moving average is $111.18. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.06 and a current ratio of 1.06. Amedisys, Inc. has a 1 year low of $83.00 and a 1 year high of $179.91.

Amedisys (NASDAQ:AMEDGet Rating) last released its quarterly earnings data on Thursday, October 27th. The health services provider reported $1.15 earnings per share for the quarter, missing the consensus estimate of $1.22 by ($0.07). The business had revenue of $557.99 million for the quarter, compared to analyst estimates of $579.30 million. Amedisys had a return on equity of 16.00% and a net margin of 5.45%. Amedisys’s revenue was up .8% compared to the same quarter last year. During the same quarter last year, the company earned $1.53 EPS. Equities analysts forecast that Amedisys, Inc. will post 4.84 earnings per share for the current fiscal year.

About Amedisys

(Get Rating)

Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness.

Recommended Stories

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMEDGet Rating).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.